Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling

Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling

Publication: Acta Pharmacol Sin
Software: GastroPlus®

To develop and evaluate a whole-body physiologically based pharmacokinetic (WB-PBPK) model of bisoprolol and to simulate its exposure and disposition...

Design, Synthesis and Testing of Novel Antimalarial Drug Leads Using in silico Tools

Design, Synthesis and Testing of Novel Antimalarial Drug Leads Using in silico Tools

Conference: ISSX
Software: ADMET Predictor®
Division: PBPK

The World Health Organization has estimated that over 200 million people suffered from malaria in 2010 and that over 600,000 people died from it that year [1]. Growing problems with resistance to existing anti­…

PBPK Model Simulation of CYP3A4 and Transporter Mediated Drug-drug Interactions Involving Erythromycin

PBPK Model Simulation of CYP3A4 and Transporter Mediated Drug-drug Interactions Involving Erythromycin

Conference: AAPS
Software: GastroPlus®
Division: PBPK

Erythromycin, a macrolide antibiotic, is cleared primarily by cytochrome P450-3A4 metabolism to the N-demethylated metabolite and C-formaldehyde. Its uptake into hepatocytes is mediated by organic…

Novel Antimalarial Drug Candidates Generated in silico by Analysis of Public HTS Data

Novel Antimalarial Drug Candidates Generated in silico by Analysis of Public HTS Data

Conference: AAPS
Division: PBPK

Carry out a prospective experiment to demonstrate the ability of in silico drug design tools to design new lead drug candidates from phenotypic screening data.

Prediction of Amoxicillin Pharmacokinetics in Populations with Altered Renal Function

Prediction of Amoxicillin Pharmacokinetics in Populations with Altered Renal Function

Conference: AAPS
Software: GastroPlus®
Division: PBPK

Purpose of the study was to predict amoxicillin pharmacokinetics in populations with altered renal function to further validate an absorption/PBPK model for amoxicillin.

Physiologically Based Pharmacokinetic (PBPK) Modeling of Amoxicillin Absorption and Pharmacokinetics

Physiologically Based Pharmacokinetic (PBPK) Modeling of Amoxicillin Absorption and Pharmacokinetics

Conference: AAPS
Software: GastroPlus®
Division: PBPK

Purpose of the study was to develop a PBPK model for amoxicillin incorporating saturable transport processes affecting the drug’s absorption and distribution.

PBPK Modeling of Erythromycin Absorption and Disposition Mediated by Transporters in Humans

PBPK Modeling of Erythromycin Absorption and Disposition Mediated by Transporters in Humans

Conference: AAPS
Division: PBPK

Erythromycin, a macrolide antibiotic, is cleared primarily by cytochrome P450-3A4 metabolism. Its uptake into enterocytes and hepatocytes is mediated by organic anion transporter (OAT) and organic anion…

The Use of Modeling Tools to Drive Efficient Oral Product Design

The Use of Modeling Tools to Drive Efficient Oral Product Design

Authors: Mathias NR, Crison J
Publication: AAPS J
Software: GastroPlus®

Modeling and simulation of drug dissolution and oral absorption has been increasingly used over the last decade to understand drug behavior in vivo based on the physicochemical properties of Active...

Preclinical Assessment of the Absorption and Disposition of the Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor GDC-0980 and Prediction of Its Pharmacokinetics and Efficacy in Human

Preclinical Assessment of the Absorption and Disposition of the Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor GDC-0980 and Prediction of Its Pharmacokinetics and Efficacy in Human

Publication: Drug Metab Dispos
Software: GastroPlus®

The objectives of these studies were to characterize the absorption and disposition of GDC-0980 and assess its efficacy in an MCF7-neo/HER2 human breast cancer xenograft model in immunocompromised mice.

Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates – An evaluation and case study using GastroPlus™

Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates – An evaluation and case study using GastroPlus™

Publication: Eur J Pharm Sci
Software: GastroPlus®

First pass metabolism in the intestinal mucosa is a determinant of oral bioavailability of CYP3A substrates and so the prediction of intestinal availability (Fg) of potential drug candidates is important.

Predicting feasibility and characterizing performance of extended-release formulations using physiologically based pharmacokinetic modeling

Predicting feasibility and characterizing performance of extended-release formulations using physiologically based pharmacokinetic modeling

Publication: Ther Deliv
Software: GastroPlus®

This review presents nine case studies where physiologically based pharmacokinetic modeling has been used in the design and development of extended-release formulations.